"Biotechs Use Gene Silencing for Extended Obesity Drug Efficacy"
Biotech companies are exploring RNA interference to develop longer-lasting obesity treatments, potentially shifting from weekly hormone-targeting drugs like Wegovy to less frequent, gene-targeted therapies.